Innoveren Scientific (IVRN) 10-Q 13 Aug 21 2021 Q2 Quarterly report Financial data

Cover

Cover - shares	6 Months Ended
	Jun. 30, 2021	Aug. 11, 2021
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Jun. 30, 2021
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2021
Current Fiscal Year End Date	--12-31
Entity File Number	001-36763
Entity Registrant Name	H-CYTE, INC
Entity Central Index Key	0001591165
Entity Tax Identification Number	46-3312262
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	201 East Kennedy Blvd
Entity Address, Address Line Two	Suite 425
Entity Address, City or Town	Tampa
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33602
City Area Code	(844)
Local Phone Number	633-6839
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	HCYT
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		148,596,889

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Current Assets
Cash	$ 1,516,522	$ 1,640,645
Patient financing receivable, current portion	22,990
Other receivables	1,809	22,123
Prepaid expenses	156,020	94,434
Total Current Assets	1,697,341	1,757,202
Right-of-use asset	183,685	278,552
Property and equipment, net	40,644	139,175
Patient financing receivable, net of current portion	42,470
Other assets	18,412	29,239
Total assets	1,982,552	2,204,168
Current Liabilities
Accounts payable	955,691	1,006,968
Accrued liabilities	208,025	276,415
Other current liabilities	212,310	154,812
Notes payable, current portion	67,444	67,444
Convertible notes payable, related parties	1,554,220
Convertible notes payable	1,070,118
PPP Loan, current portion	809,082	606,811
Deferred revenue	542,198	634,149
Lease liability, current portion	90,276	139,189
Interest payable	13,610	6,898
Total Current Liabilities	5,522,974	2,892,686
Long-term Liabilities
Lease liability, net of current portion	111,096	157,050
PPP Loan, net of current portion		202,271
Total Long-term Liabilities	111,096	359,321
Total Liabilities	5,634,070	3,252,007
Stockholders’ Equity (Deficit)
Preferred Stock - $.001 par value: 1,000,000,000 shares authorized; Series A Preferred Stock - $.001 par value: 800,000,000 shares authorized, 520,305,884 and 538,109,409 shares issued and outstanding at June 30, 2021 and December 31, 2020, respectively	520,305	538,109
Common stock - $.001 par value: 1,600,000,000 shares authorized, 144,962,989 and 127,159,464 shares issued and outstanding at June 30, 2021 and December 31, 2020, respectively	144,963	127,159
Additional paid-in capital	43,377,999	42,515,999
Accumulated deficit	(47,324,653)	(43,858,974)
Non-controlling interest	(370,132)	(370,132)
Total Stockholders’ Deficit	(3,651,518)	(1,047,839)
Total Liabilities and Stockholders’ Deficit	$ 1,982,552	$ 2,204,168

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2021	Dec. 31, 2020
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	1,000,000,000	1,000,000,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	1,600,000,000	1,600,000,000
Common stock, shares issued	144,962,989	127,159,464
Common stock, shares outstanding	144,962,989	127,159,464
Series A Preferred Stock [Member]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	800,000,000	800,000,000
Preferred stock, shares issued	520,305,884	538,109,409
Preferred stock, shares outstanding	520,305,884	538,109,409

Consolidated Statements of Oper

Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Income Statement [Abstract]
Revenues	$ 450,456	$ 19,500	$ 826,625	$ 1,036,276
Cost of Sales	(216,018)	(70,011)	(414,668)	(446,827)
Gross Profit	234,438	(50,511)	411,957	589,449
Operating Expenses
Salaries and related costs	586,119	594,447	1,247,894	1,818,157
Share based compensation	862,000		862,000	643
Loss on disposal of property and equipment	92,804		92,804
Other general and administrative	609,641	1,034,898	1,439,755	2,265,033
Research and development		200,000		950,000
Advertising	88,000	25,935	165,228	170,553
Depreciation and amortization	1,989	17,244	13,559	39,352
Total Operating Expenses	2,240,553	1,872,524	3,821,240	5,243,738
Operating Loss	(2,006,115)	(1,923,035)	(3,409,283)	(4,654,289)
Other Income (Expense)
Other Income	2,255	6,783	3,534	9,321
Interest expense	(54,145)	(363,023)	(59,930)	(419,172)
Change in fair value of redemption put liability		(18,952)		174,707
Loss on derivative instrument		(2,306,121)		(2,306,121)
Gain on extinguishment of debt		1,300,088		1,300,088
Warrant modification expense		(70,851)		(70,851)
Change in fair value of derivative liability - warrants		(3,057,225)		(2,882,247)
Total Other Income (Expense)	(51,890)	(4,509,301)	(56,396)	(4,194,275)
Net Loss	(2,058,005)	(6,432,336)	(3,465,679)	(8,848,564)
Accrued dividends on outstanding Series B Convertible Preferred Stock		18,300		36,600
Deemed dividend on Series D Convertible Preferred Stock		120,329		278,476
Net loss attributable to common stockholders	$ (2,058,005)	$ (6,570,965)	$ (3,465,679)	$ (9,163,640)
Loss per share - Basic and Diluted	$ (0.01)	$ (0.06)	$ (0.03)	$ (0.09)
Weighted average outstanding shares - basic and diluted	138,092,414	103,430,305	135,827,192	101,634,961

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) - USD ($)	Series A Preferred Stock [Member]	Series B Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Noncontrolling Interest [Member]	Total
Beginning balance at Dec. 31, 2019		$ 6	$ 99,769	$ 28,172,146	$ (37,362,531)	$ (370,132)	$ (9,460,742)
Beginning balance, shares at Dec. 31, 2019		6,100	99,768,704
Accrued dividends on Series B Convertible Preferred Stock				(36,600)			(36,600)
Deemed dividend on Series D Convertible Preferred Stock				(241,269)			(241,269)
Adjustment of exercise price on certain warrants				(438,913)			(438,913)
Issuance of warrants to extend short-term debt				6,594			6,594
Conversion of short-term notes, related parties			4,368	214,046			218,414
Deemed dividend on Series D Convertible Preferred Stock at issuance					(37,207)		(37,207)
Issuance of warrants in connection with Series D Convertible Preferred Stock				31,902			31,902
Issuance of common stock in exchange for consulting fees incurred			$ 109	34,891			35,000
Issuance of common stock in exchange for consulting fees incurred, shares			109,375
Issuance of warrants pursuant to extension of maturity date on short-term notes, related party				17,636			17,636
Share based compensation				643			643
Net loss					(8,848,564)		(8,848,564)
Ending balance at Jun. 30, 2020		$ 6	$ 104,246	27,761,076	(46,248,302)	(370,132)	(18,753,106)
Ending balance, shares at Jun. 30, 2020		6,100	104,246,357
Beginning balance at Mar. 31, 2020		$ 6	$ 99,878	28,117,978	(39,815,966)	(370,132)	(11,968,236)
Beginning balance, shares at Mar. 31, 2020		6,100	99,878,079
Accrued dividends on Series B Convertible Preferred Stock				(18,300)			(18,300)
Deemed dividend on Series D Convertible Preferred Stock				(120,329)			(120,329)
Adjustment of exercise price on certain warrants				(438,913)			(438,913)
Issuance of warrants to extend short-term debt				6,594			6,594
Conversion of short-term notes, related parties			$ 4,368	214,046			218,414
Conversion of Short-term notes, related parties, shares			4,368,278
Net loss					(6,432,336)		(6,432,336)
Ending balance at Jun. 30, 2020		$ 6	$ 104,246	27,761,076	(46,248,302)	(370,132)	(18,753,106)
Ending balance, shares at Jun. 30, 2020		6,100	104,246,357
Beginning balance at Dec. 31, 2020	$ 538,109		$ 127,159	42,515,999	(43,858,974)	(370,132)	(1,047,839)
Beginning balance, shares at Dec. 31, 2020	538,109,409		127,159,464
Issuance of warrants to extend short-term debt
Conversion of Series A Preferred Stock to common stock	$ (17,804)		$ 17,804
Conversion of Series A Preferred Stock to Common Stock, shares	(17,803,525)		17,803,525
Share based compensation				862,000			862,000
Net loss					(3,465,679)		(3,465,679)
Ending balance at Jun. 30, 2021	$ 520,305		$ 144,963	43,377,999	(47,324,653)	(370,132)	(3,651,518)
Ending balance, shares at Jun. 30, 2021	520,305,884		144,962,989
Beginning balance at Mar. 31, 2021	$ 528,429		$ 136,839	42,515,999	(45,266,648)	(370,132)	(2,455,513)
Beginning balance, shares at Mar. 31, 2021	528,429,575		136,839,298
Conversion of Series A Preferred Stock to common stock	$ (8,124)		$ 8,124
Conversion of Series A Preferred Stock to Common Stock, shares	(8,123,691)		8,123,691
Share based compensation				862,000			862,000
Net loss					(2,058,005)		(2,058,005)
Ending balance at Jun. 30, 2021	$ 520,305		$ 144,963	$ 43,377,999	$ (47,324,653)	$ (370,132)	$ (3,651,518)
Ending balance, shares at Jun. 30, 2021	520,305,884		144,962,989

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Cash Flows from Operating Activities
Net loss	$ (3,465,679)	$ (8,848,564)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	13,559	39,352
Amortization of debt discount		242,627
Issuance of warrants pursuant to short-term notes, related party		17,636
Issuance of warrants to extend short-term debt		6,594
Share based compensation expense	862,000	643
Common stock issued for consulting services		35,000
Change in fair value of derivative liability - warrants and redemption put liability		2,707,541
Change in fair value of derivative liability - loss on derivative instrument		2,306,121
Warrant modification expense		70,851
Loss on disposal of property and equipment	92,804
Gain on extinguishment of debt		(1,300,088)
Changes in operating assets and liabilities:
Accounts receivable		19,667
Patient financing receivable, current portion	(22,990)
Other receivables	20,314	14,782
Patient financing receivable, net of current portion	(42,470)
Prepaid expenses and other assets	(50,759)	668,656
Interest payable	6,712	158,113
Accounts Payable	(51,277)	(164,792)
Accrued liabilities	(68,390)	(72,619)
Other current liabilities	57,498	62,581
Deferred revenue	(91,951)	(299,125)
Net Cash Used in Operating Activities	(2,740,629)	(4,335,024)
Cash Flows from Investing Activities
Purchase of property and equipment	(7,832)
Net Cash Used in Investing Activities	(7,832)
Cash Flows from Financing Activities
Proceeds from convertible notes payable, related parties	1,554,220
Proceeds from convertible notes payable	1,070,118
Payments on debt obligations		(10,937)
Proceeds from paycheck protection program loan		809,082
Proceeds from warrants, net of issuance costs		3,842,695
Proceeds from issuance of Series D Convertible Preferred Stock		100,000
Net Cash Provided by Financing Activities	2,624,338	4,740,840
Net (Decrease)/ Increase in Cash	(124,123)	405,816
Cash - Beginning of period	1,640,645	1,424,096
Cash - End of period	1,516,522	1,829,912
Supplementary Cash Flow Information
Cash paid for interest	3,880	18,431
Non-cash investing and financing activities
Adjustment of exercise price on warrants		438,913
Issuance of warrants to extend short-term debt		6,594
Conversion of short-term notes, related parties		218,414
Deemed dividend on Series D Convertible Preferred Stock		278,476
Issuance of Warrants in connection with Series D Convertible Preferred Stock		31,902
Dividends accrued on Series B Convertible Preferred Stock		$ 36,600

Description of the Company

Description of the Company	6 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
Description of the Company	Note 1 - Description of the Company H-CYTE, Inc (“the Company”) is a hybrid-biopharmaceutical company dedicated to developing and delivering new treatments for patients with chronic respiratory and pulmonary disorders. During the last two years, the Company has evolved into two separate divisions with its entrance into the biologics development space (“Biologics Division”). This new division is complementary to the Company’s current Lung Health Institute (LHI) autologous infusion therapy business (“Infusion Division”) and is focused on underserved disease states. The consolidated results for H-CYTE include the following wholly-owned subsidiaries: H-CYTE Management, LLC, Medovex Corp, Cognitive Health Institute, LLC, and Lung Institute Tampa, LLC and the results include Lung Institute Dallas, PLLC (“LI Dallas”), Lung Institute Nashville, PLLC (“LI Nashville”), Lung Institute Pittsburgh, PLLC (“LI Pittsburgh”), and Lung Institute Scottsdale, LLC (“LI Scottsdale”), as Variable Interest Entities (“VIEs”). Additionally, H-CYTE Management, LLC is the operator and manager of the various Lung Health Institute (LHI) clinics: LI Dallas, LI Nashville, LI Pittsburgh, and LI Scottsdale. The LI Dallas and LI Pittsburgh clinics did not reopen in 2020 after the temporary closure of all LI clinics due to COVID-19. These two clinics will remain permanently closed. On September 11, 2020, with the closing of the Rights Offering, FWHC, LLC, FWHC Bridge, LLC, and FWHC Bridge Friends, LLC (collectively known as “FWHC”) gained control of the Company by subsequently owning approximately 61% of the fully diluted shares of the Company (for further discussion, see Notes 8 and 9-“Equity Transactions” to the consolidated financial statements in the Company’s 2020 Annual Report on Form 10-K). Autologous Infusion Therapy (“Infusion Division”) The Infusion Division develops and implements innovative treatment options in autologous cellular therapy (PRP-PBMC) to treat chronic lung disorders. Committed to an individualized patient-centric approach, this division provides oversight and management of the highest quality to the LHI clinics, while producing positive medical outcomes following the strictest Centers for Disease Control and Prevention (the “CDC”) guidelines. Biotech Development (“Biologics Division”) On June 21, 2019, H-CYTE entered into an exclusive product supply agreement with Rion, LLC (“Rion”) to develop and distribute (post U.S. Food & Drug Administration, the “FDA”, approval) a biologic combining its PRP-PBMC technology with Rion’s exosomes (“EV”) technology for the treatment of chronic obstructive pulmonary disease (“COPD”), the fourth leading cause of death in the U.S. Rion has established a novel EV technology to harness the healing power of the body. Rion’s innovative technology, based on science developed at Mayo Clinic, provides an off-the-shelf platform to enhance healing in soft tissue, musculoskeletal, cardiovascular, and neurological organ systems. This agreement provides for a 10 -year exclusive and extendable supply agreement with Rion to enable H-CYTE to develop combined proprietary biologics. The Company is currently evaluating the potential of a combined biologic and the utilization of this agreement. On October 9, 2019, the Company entered into a services agreement with Rion which provides the Company the benefit of Rion’s resources and expertise for the limited purpose of (i) consulting with and assisting H-CYTE in the further research and development for the generation of a new biologic and (ii) subsequently assisting H-CYTE in seeking and obtaining FDA Phase 1 IND clearance for this biologic as necessary. Rion has also agreed to consult with H-CYTE in its arrangement for services from third parties unaffiliated with Rion to support research, development, regulatory approval, and commercialization of its efforts. After conducting the clinical efficacy trials of this biologic, the Company intends to pursue submission of a Biologics License Application (“BLA”) for review by the FDA for treatment of COPD or similar lung disorders. On April 2, 2021, the Company entered into a series of agreements with Medovex, LLC to pursue a joint venture regarding the continued development and commercialization of the DenerveX device for business outside of the U.S. The Company has determined that the transactions resulting from the series of agreements with Medovex, LLC are immaterial. The Company will assess the progress of the joint venture on a quarterly basis for materiality.

Basis of presentation

Basis of presentation	6 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
Basis of presentation	Note 2 – Basis of presentation The accompanying interim consolidated financial statements have been prepared based upon U.S. Securities and Exchange Commission rules that permit reduced disclosure for interim periods. Therefore, they do not include all information and footnote disclosures necessary for a complete presentation of the Company’s financial position, results of operations, and cash flows in conformity with generally accepted accounting principles. The Company filed audited consolidated financial statements as of and for the fiscal years ended December 31, 2020 and 2019, which included all information and notes necessary for such complete presentation in conjunction with its 2020 Annual Report on Form 10-K. The results of operations for the interim period ended June 30, 2021 are not necessarily indicative of the results to be expected for any future period or the entire fiscal year. These interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements for the year ended December 31, 2020, which are contained in the Company’s 2020 Annual Report on Form 10-K. For further discussion refer to Note 2–“Basis Of Presentation And Summary of Significant Accounting Policies” to the consolidated financial statements and “Management’s Discussion and Analysis of Financial Condition and Results of Operations–Critical Accounting Policies and Estimates” in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020.

Liquidity, Going Concern and Ma

Liquidity, Going Concern and Management’s Plans	6 Months Ended
	Jun. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Liquidity, Going Concern and Management’s Plans	Note 3 - Liquidity, Going Concern and Management’s Plans The Company incurred net losses of approximately $ 2,058 ,000 and $ 3,466 ,000 and for the three months and six months ended June 30, 2021. The Company has historically incurred losses from operations and expects to continue to generate negative cash flows as it implements its plan around the Biosciences Division. The interim consolidated financial statements are prepared using accounting principles generally accepted in the United States (“U.S. GAAP”) as applicable to a going concern. COVID-19 has adversely affected the Company’s financial condition and results of operations. The impact of the outbreak of COVID-19 on the economy in the U.S. and the rest of the world is expected to continue to be significant. The extent to which the COVID-19 outbreak will continue to impact the economy is highly uncertain and cannot be predicted. Accordingly, the Company cannot predict the extent to which its financial condition and results of operations will be affected. Convertible Notes Payable On April 1, 2021, the Company, entered into a Secured Convertible Note Purchase Agreement (the “April 2021 Note Purchase Agreement”) with five (5) investors (the “Holders”). Pursuant to the terms of the April 2021 Note Purchase Agreement, the Company sold promissory notes in the aggregate principal amount of $ 2,575,000 maturing on March 31, 2022 with an annual interest rate of 8% . The Notes, plus accrued interest, are convertible into shares of Common Stock at a discount of 20% to the price paid for such New Securities in the next round of financing that meets the definition of Qualified Financing as defined in the April 2021 Note Purchase Agreement. The Notes are secured by the assets of the Company under a security agreement with the Holders. The lead investor of the April 2021 Note Purchase Agreement, FWHC Bridge, LLC, advanced $ 1,500,000 of the total amount to the Company. FWHC Bridge, LLC is an affiliated entity of FWHC, LLC, which is a principal stockholder and related party of the Company. An additional affiliate of FWHC, LLC provided an additional $ 25,000 as part of the April 2021 Note Purchase Agreement. The Company chose early adoption of ASU 2020-06 Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity The Company had cash on hand of approximately $ 1,516,000 as of June 30, 2021 and approximately $ 1,099,000 There can be no assurance that the Company will be able to raise additional funds or that the terms and conditions of any future financings will be workable or acceptable to the Company or its shareholders. If the Company is unable to fund its operations from existing cash on hand, operating cash flows, additional borrowings, or raising equity capital, the Company may be forced to discontinue operations. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

Right-of-use Asset And Lease Li

Right-of-use Asset And Lease Liability	6 Months Ended
	Jun. 30, 2021
Right-of-use Asset And Lease Liability
Right-of-use Asset And Lease Liability	Note 4 – Right-of-use Asset And Lease Liability The components of lease expense, which are included in other general and administrative expense, for the three months and six months ended June 30, 2021 and 2020, respectively, are as follows: SCHEDULE OF COMPONENTS OF LEASE EXPENSE Three Months Ended June 30, Six Months Ended June 30, 2021 2020 2021 2020 Operating lease expense $ 75,058 $ 151,464 $ 183,650 $ 302,028 Cash paid for amounts included in the measurement of lease liabilities for the three months and six months ended June 30, 2021 and 2020, respectively, are as follows: SCHEDULE OF CASH PAID FOR AMOUNTS INCLUDED THE MEASUREMENT OF LEASE LIABILITIES Three Months Ended June 30, Six Months Ended June 30, 2021 2020 2021 2020 Operating cash flows from operating leases $ 75,058 $ 151,464 $ 183,650 $ 302,028 Supplemental balance sheet and other information related to operating leases are as follows: SCHEDULE OF SUPPLEMENTAL BALANCE SHEET AND OTHER INFORMATION June 30, 2021 December 31, 2020 Operating leases right-of-use assets $ 183,685 $ 278,552 Lease liability, current portion 90,276 139,189 Lease liability, net of current portion 111,096 157,050 Total operating lease liabilities $ 201,372 $ 296,239 Weighted average remaining lease term 2.17 2.32 Weighted average discount rate 10.73 % 10.31 % Future maturities of operating lease liabilities as of June 30, 2021 are as follows: SCHEDULE OF MATURITIES OF LEASE LIABILITIES Operating leases Remainder of 2021 $ 50,752 2022 102,891 2023 69,333 Total lease payments 222,976 Less: Interest (21,604 ) Total lease liability $ 201,372 The Company did not renew its corporate office space lease in Tampa, FL which expired on March 31, 2021. The Company leases medical clinic space in Tampa, FL, Nashville, TN, and Scottsdale, AZ. These clinic locations have various expiration dates through August 31, 2023. The leasing arrangements contain various renewal options that are adjusted for increases in the consumer price index or agreed upon rates. The Company entered into a twelve-month lease for its Tampa location beginning April 1, 2021 totalling $ 71,775 The Company decided that its corporate staff will continue working remotely but the Company will have a small corporate meeting room in the Tampa LHI clinic.

Property And Equipment

Property And Equipment	6 Months Ended
	Jun. 30, 2021
Property, Plant and Equipment [Abstract]
Property And Equipment	Note 5 - Property And Equipment Property and equipment, net, consists of the following: SCHEDULE OF PROPERTY AND EQUIPMENT Useful Life June 30, 2021 December 31, 2020 Furniture and fixtures 5 7 $ 96,185 $ 231,222 Computers and software 3 7 213,660 246,323 Leasehold improvements 15 40,130 155,583 349,975 633,128 Less: accumulated depreciation (309,331 ) (493,953 ) Total $ 40,644 $ 139,175 Depreciation expense was approximately $ 2,000 and $ 14,000 for the three and six months ended June 30, 2021, respectively. Depreciation expense was approximately $ 17,000 and $ 39,000 for the three months and six months ended June 30, 2020, respectively. The Company uses the straight-line depreciation method to calculate depreciation expense. The Company recorded a loss on disposal of approximately $ 93,000 for the three and six months ended June 30, 2021.

Related Party Transactions

Related Party Transactions	6 Months Ended
	Jun. 30, 2021
Related Party Transactions [Abstract]
Related Party Transactions	Note 6 – Related Party Transactions Board Members and Officers and Related Expenses Effective February 1, 2019, the Company entered into an oral consulting agreement with Mr. Raymond Monteleone, Board Member and Chairman of the Audit Committee in which Mr. Monteleone received $ 10,000 per month for advisory services and $ 5,000 per quarter as Audit Committee Chair in addition to regular quarterly board meeting fees. Effective March 25, 2020, the Company reduced the advisory services to $ 5,000 per month and the fees per quarter as the Audit Committee Chair to $ 2,500 per quarter. On January 12, 2021, Mr. Monteleone was appointed as Chairman of the Board and Compensation Committee Chair. There are understandings between the Company and Mr. Monteleone for him to receive $ 4,167 per month to serve on the Board of Directors and an additional $ 5,000 per quarter to serve as Chairman of the Board, Audit Committee Chair, and Compensation Committee Chair. The Company expensed approximately $ 17,500 and $ 35,000 in compensation to Mr. Monteleone for the three months and six months ended June 30, 2021, respectively. The Company expensed approximately $ 17,500 47,500 Effective October 1, 2020, the Company entered into an oral agreement with Mr. Michael Yurkowsky in which Mr. Yurkowsky will receive $ 4,167 12,500 25,000 0 On January 12, 2021, Mr. William Horne stepped down as Chairman of the Board. Mr. Horne will remain a member of the Board. Effective March 1, 2021, the Company entered into an oral agreement with Mr. Horne in which Mr. Horne will receive $ 4,167 12,500 17,000 0 Debt and Other Obligations The short-term notes, related parties and convertible notes payable, related parties are detailed in Note 3-“Liquidity, Going Concern and Management’s Plans” in this Form 10-Q. Change in Control On September 11, 2020, with the closing of the Rights Offering, FWHC, LLC, FWHC Bridge, LLC, and FWHC Bridge Friends, LLC (collectively known as “FWHC”) gained control of the Company by subsequently owning approximately 61% of the fully diluted shares of the Company. On July 28, 2020, the Company issued an aggregate of 15,518,111 shares of its common stock to FWHC upon the conversion of its issued Series D Convertible Preferred Stock. The Preferred Stock was converted pursuant to a mandatory conversion triggered by the majority holder of the Series D Convertible Preferred Stock as set forth in the Certificate of Designations for the Series D Convertible Preferred Stock. On September 11, 2020, with the closing of the Rights Offering, FWHC was issued 123,031,819 shares of Preferred A Stock for conversion of the outstanding promissory notes from April 2020, 75,162,429 shares of Preferred A Stock for conversion of the April Secured Note, 35,860,079 shares of Preferred A Stock for conversion of the Hawes Notes, and 117,362,143 shares of Preferred A Stock issued upon the closing of the Rights Offering. FWHC was also issued 273,356,676 10 -year warrants at $ 0.014 upon the closing of the Rights Offering. Convertible Notes Payable On April 1, 2021, the Company, entered into a Secured Convertible Note Purchase Agreement (the “April 2021 Note Purchase Agreement”) with five (5) investors (the “Holders”). Pursuant to the terms of the April 2021 Note Purchase Agreement, the Company sold promissory notes in the aggregate principal amount of $ 2,575,000 March 31, 2022 8 20 1,500,000 25,000

Equity Transactions

Equity Transactions	6 Months Ended
	Jun. 30, 2021
Equity [Abstract]
Equity Transactions	Note 7 - Equity Transactions Common Stock Issuance In February 2020, the Company issued LilyCon Investments $ 35,000 0.32 109,375 On April 23, 2020, Horne Management, LLC agreed to convert the related notes plus accrued interest into (i) 4,368,278 ten-year 0.014 On July 28, 2020, the Company issued an aggregate of 17,893,076 On July 29, 2020, the Company filed its Second Amended and Restated Certificate of Incorporation (the “Amended COI”). The Amended COI provides for the issuance of up to 1,600,000,000 shares of Common Stock and 1,000,000,000 shares of Preferred Stock, of which 800,000,000 shares are designated as Series A Preferred Stock and eliminates the previously authorized classes of preferred stock. The Amended COI also delineates the rights of the Series A Preferred Stock. Series A Preferred Stock On September 11, 2020, the registered Rights Offering (Registration No. 333-239629) of the Company expired. Pursuant to the Rights Offering, on September 24, 2020, the Company issued (i) 15,235,381 0.014 203,049,643 3,055,985 Additionally, on September 24, 2020, the Company issued an aggregate of 323,844,416 shares of its Series A Preferred Stock to the holders of outstanding promissory notes, issued in April 2020, in the aggregate principal amount and accrued interest of $ 4,483,617 . The notes were converted pursuant to a mandatory conversion triggered by the completion of the Rights Offering (for further discussion, see Note 9-“Equity Transactions” to the consolidated financial statements in the Company’s 2020 Annual Report on Form 10-K). During the three and six months ended June 30, 2021, 8,123,691 and 17,803,525 shares of Series A Preferred Stock were converted to Common Stock at the request of certain Series A Preferred Shareholders. Voting Rights Holders of Series A Preferred Stock (“Series A Holders”) have the right to receive notice of any meeting of holders of common stock and to vote upon any matter submitted to a vote of the holders of common stock. Each Series A Holder shall vote on each matter on an as converted basis submitted to them with the holders of common stock. Conversion Series A Preferred Stock converts to common stock at a 1:1 ratio Liquidation Series A Preferred Stock does not have preferential treatment over common stock shareholders if the Company liquidates or dissolves. Share -Based Compensation The Company utilizes the Black-Scholes valuation method to recognize share-based compensation expense over the vesting period. The expected life represents the period that the stock-based compensation awards are expected to be outstanding. Stock Option Activity On April 1, 2021, the Board of Directors of the Company approved and granted to certain directors and officers of the Company an aggregate of 54,750,000 stock options of which 4,750,000 were immediately vested on the date of grant. Each option granted has an exercise price of $ 0.07 per share and an expiration date of ten years from the date of grant. These options are not included in the Company’s current stock option plan as they were granted outside of the plan. For the six months ended June 30, 2020, all outstanding stock options were fully vested, and related compensation expense recognized. For the six months ended June 30, 2021, 55,135,000 options were outstanding and 5,718,133 were vested. As of June 30, 2021, the Company recognized $ 862,000 in stock-based compensation expense and has approximately $ 2,150,000 of unrecognized compensation costs related to non-vested stock options, which is expected to be recognized over a weighted average period of approximately 3.24 years. Inputs used in the valuation models are as follows: SCHEDULE OF ASSUMPTIONS USED TO CALCULATE FAIR VALUE OF STOCK OPTIONS 2021 Grants Option value $ 0.054 to $ 0.056 Risk Free Rate 0.90 % to 1.37 % Expected Dividend- yield - to - Expected Volatility 173.99 % to 176.04 % Expected term (years) 5 to 7 The following is a summary of stock option activity for the six months ended June 30, 2020 and 2021: SUMMARY OF STOCK OPTION ACTIVITY Shares Weighted Average Exercise Price Weighted Average Remaining Term (Years) Outstanding at December 31, 2019 425,000 $ 1.38 7.71 Granted — — — Expired/Cancelled (15,000 ) 1.35 — Outstanding and exercisable at June 30, 2020 410,000 $ 1.39 7.23 Outstanding at December 31, 2020 410,000 $ 1.39 6.72 Granted 54,750,000 0.07 9.75 Expired/Cancelled (25,000 ) 2.16 — Outstanding at June 30, 2021 55,135,000 $ 0.08 9.73 Exercisable at June 30, 2021 5,718,333 $ 0.16 9.52 The following is a summary of the Company’s non-vested shares for the six months ended June 30, 2021: SUMMARY OF STOCK OPTION ACTIVITY NON-VESTED Shares Weighted Average Grant Date Fair Value Non-vested at December 31, 2020 - $ - Granted 54,750,000 0.06 Vested (5,333,333 ) 0.05 Forfeited - - Non-vested at June 30, 2021 49,416,667 $ 0.06 Non-Controlling Interest For the six months ended June 30, 2021 and 2020, the Company consolidated the results for LI Dallas, LI Nashville, LI Pittsburgh, and LI Scottsdale as VIEs. The Company owns no portion of any of these four entities, however, the Company maintains control through their management role for each of the clinics, in accordance with each clinic’s respective management services agreement. Based on these agreements, the Company has the responsibility to run and make decisions on behalf of the clinics, except for medical care and procedures. Beginning in January 2018, the Company adopted the policy, for all of the VIEs, that the management fee charged by the Company would equal the amount of net income from each VIE on a monthly basis, bringing the amount of the net income to $0 each month for the VIEs. Due to this change in policy, there was no change in the non-controlling interest for the six months ended June 30, 2021 or 2020 related to the net income (loss) as it was $ 0 Net Loss Per Share Basic loss per share is computed on the basis of the weighted average number of shares outstanding for the reporting period. Diluted loss per share is computed on the basis of the weighted average number of common shares plus dilutive potential common shares outstanding using the treasury stock method. Any potentially dilutive securities are antidilutive due to the Company’s net losses. The Company excluded the following securities from the calculation of basic and diluted net loss per share as the effect would have been antidilutive: SCHEDULE OF ANTIDILUTIVE SECURITIES OF BASIC AND DILUTED NET LOSS PER SHARE For the Six Months Ended June 30, 2021 2020 Options to purchase common stock (in the money) 4,977,273 410,000 Warrants to purchase common stock (in the money) 386,908,082 404,821,082 Series A Preferred Stock convertible to common stock 520,305,884 - Series B & D Preferred Stock convertible to common stock - 38,308,600 Total 912,191,239 443,539,682 Excluded from the above table are 23,149,370 385,000 0.08

Commitments & Contingencies

Commitments & Contingencies	6 Months Ended
	Jun. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments & Contingencies	Note 8 – Commitments & Contingencies Litigation From time to time, the Company may be involved in routine legal proceedings, as well as demands, claims and threatened litigation that arise in the normal course of our business. The ultimate amount of liability, if any, for any claims of any type (either alone or in the aggregate) may materially and adversely affect the Company’s financial condition, results of operations, and liquidity. In addition, the ultimate outcome of any litigation is uncertain. Any outcome, whether favorable or unfavorable, may materially and adversely affect the Company due to legal costs and expenses, diversion of management attention, and other factors. The Company expenses legal costs in the period incurred. The Company cannot assure that additional contingencies of a legal nature or contingencies having legal aspects will not be asserted against the Company in the future, and these matters could relate to prior, current or future transactions or events. As of June 30, 2021, the Company had no litigation matters which required any accrual or disclosure. Guarantee The Company has guaranteed payments based upon the terms found in the management services agreements to affiliated physicians related to LI Nashville and LI Scottsdale. For the three and six months ended June 30, 2021, payments totaling approximately $ 26,000 and $ 43,000 , respectively, were made to these physicians’ legal entities. For the three and six months ended June 30, 2020, payments totaling approximately $ 0 and $ 22,000 , respectively, were made to these physicians’ legal entities. Due to COVID-19, the Company temporarily ceased operations effective March 23, 2020 in LI Dallas, LI Pittsburgh, LI Scottsdale, LI Nashville, and LI Tampa, at which time, the guaranteed payments for these clinics were suspended. The guaranteed payments did not resume for LI Dallas and LI Pittsburgh due to those clinics being permanently closed. The Company resumed guaranteed payments in January 2021 for LI Nashville and LI Scottsdale. Rion Agreements On June 21, 2019, H-CYTE entered into an exclusive product supply agreement with Rion, LLC (“Rion”) to develop and distribute (post FDA approval) a biologic for chronic obstructive pulmonary disease (“COPD”), the fourth leading cause of death in the U.S. Rion has established a novel biologics technology to harness the healing power of the body. Rion’s innovative technology, based on science developed at Mayo Clinic, provides an off-the-shelf platform to enhance healing in soft tissue, musculoskeletal, cardiovascular and neurological organ systems. This agreement provides for a 10-year exclusive and extendable supply agreement with Rion to enable H-CYTE to develop proprietary biologics. On October 9, 2019, the Company entered into a services agreement with Rion which provides the Company the benefit of Rion’s resources and expertise for the limited purpose of (i) consulting with and assisting H-CYTE in the further research and development for the generation of a new biologic and (ii) subsequently assisting H-CYTE in seeking and obtaining FDA Phase 1 IND clearance for this biologic as necessary. Rion also agrees to consult with H-CYTE in its arrangement for services from third parties unaffiliated with Rion to support research, development, regulatory approval, and commercialization of the biologic. An additional $ 350,000 in expense is expected to be incurred per the Rion Agreements. At this time, the Company is not able to estimate when this expense will occur. For the three and six months ended June 30, 2021 the Company expensed $ 0 . For the three and six months ended June 30, 2020 the Company expensed $ 200,000 and $ 950,000 , respectively.

Short-term Debt

Short-term Debt	6 Months Ended
	Jun. 30, 2021
Debt Disclosure [Abstract]
Short-term Debt	Note 9 – Short-term Debt Convertible Notes Payable Convertible Notes payable represents a securities purchase agreement with select accredited investors, which was assumed in the Asset Purchase Agreement between Medovex Corp and Regenerative Medicine Solutions, LLC (“Merger”) in 2019 (see Note 1 – “Description of the Company” to the consolidated financial statements in the Company’s 2020 Annual Report on Form 10-K). The debt assumed by the Company, as part of the merger, consisted of $ 750,000 50,000 Each Unit consists of (i) a 12% 0.001 0.40 three In 2019, $ 100,000 350,000 300,000 85,000 40,000 424,615 On April 1, 2021, the Company, entered into a Secured Convertible Note Purchase Agreement (the “April 2021 Note Purchase Agreement”) with five (5) investors (the “Holders”). Pursuant to the terms of the April 2021 Note Purchase Agreement, the Company sold promissory notes in the aggregate principal amount of $ 2,575,000 March 31, 2022 8 20 1,500,000 25,000 Interest expense is being accreted to the principal balance using the effective interest method. For the three months ended June 30, 2021, the Company recorded interest expense of $ 29,220 and $ 20,118 for related party convertible notes payable and convertible notes payable, respectively. Notes Payable Notes payable were assumed in the Merger and are due in aggregate monthly instalments of approximately $ 5,800 and carry an interest rate of 5% . Each note originally had a maturity date of August 1, 2019 . The Company finalized an eighteen-month extension to March 1, 2021 . The Company is working with the lender for an additional extension of the promissory notes. The promissory notes have an aggregate outstanding balance of approximately $ 67,000 at June 30, 2021 and December 31, 2020. The Company has not made payments on this note since February 10, 2020, due to COVID-19, resulting in accrued interest of approximately $ 5,000 . On March 27, 2020, the Company issued a demand note in the principal amount of $ 500,000 to FWHC Bridge, LLC (the “Investor”) in exchange for a loan made by the Investor in such amount to cover the Company’s working capital needs. Subsequently on April 9, 2020, in exchange for an additional loan of $ 500,000 made by the Investor to the Company, the Company amended and restated the demand note to reflect a new principal amount of $ 1,000,000 , which became the A&R Note (see Note 11-“Debt” to the consolidated financial statements in the Company’s 2020 Annual Report on Form 10-K). Paycheck Protection Program On April 29, 2020, the Company issued a promissory note in the principal amount of $ 809,082 to the Bank of Tampa in connection with a loan in such amount made under the Paycheck Protection Program (“PPP Loan”). The PPP Loan bears an interest rate of 1% per annum and matures on April 29, 2022. The Company elected to use a 24-week Covered Period, per the SBA Paycheck Protection Program guidelines, which ended on October 14, 2020. The Company can apply for loan forgiveness in an amount equal to the sum of the following costs incurred by the Company: 1) payroll costs; 2) any payment of interest on covered mortgage obligations; 3) any payment on a covered rent obligation; and 4) any covered utility payment The amount forgiven will be calculated (and may be reduced) in accordance with the Paycheck Protection Program criteria set by the SBA. Not more than 40%

Derivative Liabilities

Derivative Liabilities	6 Months Ended
	Jun. 30, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Liabilities	Note 10 – Derivative Liabilities The Company’s derivative liabilities are classified within Level 3 of the fair value hierarchy because certain unobservable inputs were used in the valuation models. These assumptions included estimated future stock prices, potential down-round financings for the Warrants, and potential redemptions for the Redemption Put Liability. The following are rollforwards of the liabilities during the six months ended June 30, 2020: SCHEDULE OF FAIR VALUE, LIABILITIES MEASURED ON RECURRING BASIS Derivative Liability - Warrants Balance at December 31, 2019 $ 315,855 Series D Warrant reclass from equity to liability 509,764 Warrants issued with modification of Horne Note 198,994 Warrants issued with April 17, 2020 financing 6,148,816 Fair value adjustments 2,882,247 Balance at June 30, 2020 $ 10,055,676 Redemption Put Liability Balance at December 31, 2019 $ 267,399 Issuance of Series D Convertible Preferred Stock 5,306 Fair value adjustments (174,707 ) Balance at June 30, 2020 $ 97,998 Derivative Liability- Warrants Series B Warrants As part of the April Offering, the holders of the Series B Warrants agreed to terminate anti-dilution price protection in their warrants and adjusted the exercise price to equal the price per share at which shares of preferred stock are offered for purchase in a Qualified Financing. The modification resulted in an increase of approximately $ 75,000 Series D Warrants In conjunction with their Series D Preferred Financing, the Company originally issued Series D warrants to purchase 14,669,757 0.75 510,000 Horne Warrants On April 23, 2020, Horne Management, LLC agreed to convert the related notes plus accrued interest into (i) 4,368,278 ten 0.05 0.014 101% 0.65% 199,000 April Bridge Loan and Converted Advance Warrants The April Offering entitled the investors to warrants with the right to purchase up to 100% of the aggregate number of shares of Common Stock into which the Purchaser’s Note may ultimately be converted. The Company also received a $1,000,000 advance which was converted into a Converted Advance Note and Converted Advance Warrants in April 2020. The Converted Advance Warrants entitle the holder to purchase up to 200% of the aggregate number of shares of Common Stock into which the Converted Advanced Note may ultimately be converted. The Company received an aggregate of $ 2,842,695 in gross proceeds through the April 2020 Offering and an advance of $ 1,000,000 which was converted into an Advance Note on April 17, 2020. The Company expected the price per share at which securities would have been offered for purchase in the Qualified Financing to be $0.014 resulting in the assumption there would be approximately 203,050,000 and 142,857,000 shares issuable upon exercise of the Purchaser Warrants and the Converted Advance Warrants, respectively. The warrants were valued using a Lattice model with the following assumptions: Trading market price- $ 0.05 , estimated exercise price- $ 0.014 , volatility- 103% , risk free rate- 0.65% and an estimated term of 10 years. At inception, the estimated fair value of the Purchaser Warrants and the Converted Advance Warrants was approximately $ 3,279,000 and $ 2,869,300 , respectively. The derivative liability has been remeasured to fair value at the end of each reporting period and the change in fair value, of approximately ($ 3,057,225 ) and ($ 2,882,247 ), has been recorded as a component of other income (expense) in the Company’s consolidated statement of operations for the three months and six months ended June 30, 2020, respectively. The Company estimated the fair value of the warrant derivative liability as of June 30, 2020 using the following assumptions: SCHEDULE OF ASSUMPTIONS FOR WARRANTS June 30, 2020 Fair value of underlying stock $ 0.05 Exercise price $ 0.014 Risk free rate 0.14 0.66 % Expected term (in years) 0.17 10.27 Stock price volatility 109 312 % Expected dividend yield — On April 17, 2020, the holders of the warrants agreed to terminate all anti-dilution price protections in their warrants. The fair value of the warrants will be significantly influenced by the fair value of the Company’s stock price, stock price volatility, changes in interest rates and management’s assumptions related to the estimated date and price of a Qualified Financing. In conjunction with the Series D Preferred financing (see note 12), the Company offered the Series B warrant holders the option to exchange their warrants on the basis of 1 warrant for 0.40 common shares. 1,007,813 75,000 403,125 73,000 Redemption Put Liability As described in Note 12, the redemption put provision embedded in the Series D financing required bifurcation and measurement at fair value as a derivative. If the redemption put provision is triggered, it allows either payment in cash or the issuance of “Trigger Event Warrants”. Accordingly, the fair value of the Redemption put liability considered management’s estimate of the probability of cash payment versus payment in Trigger Event Warrants and was valued using a Monte Carlo Simulation which uses randomly generated stock-price paths obtained through a Geometric Brownian Motion stock price simulation. The fair value of the redemption provision will be significantly influenced by the fair value of the Company’s stock price, stock price volatility, changes in interest rates and management’s assumptions related to the redemption factor. The Company estimated the fair value of the Trigger Event Warrant portion of the redemption put liability using the following assumptions on June 30, 2020: SCHEDULE OF ASSUMPTIONS FOR WARRANTS June 30, 2020 Fair value of underlying stock $ 0.05 Exercise price $ 0.20409 Risk free rate 0.66 % Expected term (in years) 9.5 Stock price volatility 107 % Expected dividend yield — The fair market value of the redemption put liability at inception was approximately $ 614,000 which has been recorded as a liability and is remeasured to fair value at the end of each reporting period. The change in fair value of approximately ($ 19,000 ) and $ 175,000 has been recorded as a component of other income (expense) in the Company’s consolidated statement of operations for the three and six months ended June 30, 2020, respectively. The Company did not have any assets or liabilities measured at fair value using Level 1 or 2 of the fair value hierarchy as of December 31, 2020 (see Note 12-“Derivative Liability-Warrants and Redemption Put” to the consolidated financial statements in the Company’s 2020 Annual Report on Form 10-K).

Common Stock Warrants

Common Stock Warrants	6 Months Ended
	Jun. 30, 2021
Common Stock Warrants
Common Stock Warrants	Note 11 - Common Stock Warrants A summary of the Company’s warrant issuance activity and related information for the period ended June 30, 2021 and 2020 is as follows: SUMMARY OF WARRANT ACTIVITY Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Life Outstanding and exercisable at December 31, 2019 44,806,076 $ 0.78 4.59 Issued 5,178,720 0.015 9.79 Outstanding and exercisable at June 30, 2020 49,984,796 $ 0.104 9.16 Issued, not yet exercisable (1) 354,836,286 0.014 9.79 Total outstanding at June 30, 2020 404,821,082 0.104 9.16 Outstanding and exercisable at December 31, 2020 413,423,972 $ 0.015 10.30 Expired (3,366,520 ) $ 0.32 — Issued — — — Total outstanding and exercisable at June 30, 2021 410,057,452 $ 0.63 8.63 (1) The Company had estimated on June 30, 2020 that the number of warrants to be granted for the bridge financing would be 354,836,286 9,602,890 364,439,176 1,292,411 The fair value of all warrants issued are determined by using the Black-Scholes valuation technique and were assigned based on the relative fair value of both the common stock and the warrants issued. The inputs used in the Black-Scholes valuation technique to value each of the warrants as of their respective issue dates are as follows: SCHEDULE OF ASSUMPTIONS FOR WARRANTS Event Description Date Number of Warrants H-CYTE Stock Price Exercise Price of Warrant Grant Date Fair Value Life of Warrant Risk Free Rate of Return (%) Annualized Volatility Rate (%) Short-term note, related party 1/13/2020 268,571 $ 0.12 $ 0.75 $ 0.07 3 1.60 145.76 Private placement of Series D Convertible Preferred Stock 1/17/2020 244,996 $ 0.15 $ 0.75 $ 0.13 10 1.84 144.30 Granted for bridge financing 4/8/2020 296,875 $ 0.05 $ 0.40 $ 0.04 3 0.34 131.82 Short-term note, related party conversion 4/17/2020 4,368,278 $ 0.05 $ 0.014 $ 0.05 10 0.65 100.64 Granted for bridge financing 9/11/2020 364,439,176 $ 0.05 $ 0.014 $ 0.017 10 0.65 96.97 The methods described above may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, while the Company believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.

Series D Convertible Preferred

Series D Convertible Preferred Stock	6 Months Ended
	Jun. 30, 2021
Equity [Abstract]
Series D Convertible Preferred Stock	Note 12 - Series D Convertible Preferred Stock On November 15, 2019, the Company entered into a securities purchase agreement with selected accredited investors whereby the Company offered (i) up to 238,871 40.817 ten-year 14,669,757 10 0.75 On November 21, 2019, the Company entered into a securities purchase agreement with FWHC Holdings, LLC (“FWHC”) an accredited investor for the purchase of 146,998 shares of Series D Convertible Preferred Stock, par value $ 0.001 per share and the Series D Warrant (the “FWHC Investment”; see note 14-“Mezzanine Equity and Series D Convertible Preferred Stock” to the consolidated financial statements in the Company’s 2020 Annual Report on Form 10-K). For the six months ended June 30, 2021 and 2020, the Company recorded $ 0 278,476 in deemed dividends on the Series D Convertible Preferred Stock in accordance with the 8 % stated dividend resulting in a total balance of Series D Convertible Preferred stock of $ 6,281,433 at June 30, 2020. All outstanding shares of Series D Convertible Preferred Stock were converted into 15,773,363 shares of Common Stock on July 28, 2020. The conversion was pursuant to a mandatory conversion triggered by the majority holder of the Series D Convertible Preferred Stock as set forth in the Certificate of Designations. As of December 31, 2020, the Company does not have any Series D Convertible Preferred Stock outstanding (see Note 9-“Equity Transactions” to the consolidated financial statements in the Company’s 2020 Annual Report on Form 10-K).

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2021
Income Tax Disclosure [Abstract]
Income Taxes	Note 13 – Income Taxes The Company utilizes the liability method of accounting for income taxes as set forth in FASB ASC Topic 740, “Income Taxes”. Under the liability method, deferred taxes are determined based on temporary differences between the financial statement and tax bases of assets and liabilities using tax rates expected to be in effect during the years in which the difference turns around. The Company accounts for interest and penalties on income taxes as income tax expense. A valuation allowance is recorded when it is more likely than not that a tax benefit will not be realized. In determining the need for valuation allowances the Company considers projected future taxable income and the availability of tax planning strategies. From inception to June 30, 2021, the Company has incurred net losses and, therefore, has no current income tax liability. The net deferred tax asset generated by these losses is fully offset by a valuation allowance as of June 30, 2021 and December 31, 2020. Management of the Company evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets and determined that it is more likely than not that the Company will not recognize the full benefits of the deferred tax assets. The Company’s policy is to record interest and penalties on uncertain tax positions as a component of income tax expense. There are no

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2021
Subsequent Events [Abstract]
Subsequent Events	N ote 14 - Subsequent Events Effective July 13, 2021, Tanya Rhodes, the Company’s Chief Technology Officer, was designated as an Executive Officer of the Company. As of August 11, 2021, an additional 3,633,900 The Company has evaluated subsequent events through August 13, 2021 and has determined that there have been no events that would require adjustments to or disclosure in the June 30, 2021 interim Consolidated Financial Statements other than those disclosed in this Form 10-Q.

Right-of-use Asset And Lease _2

Right-of-use Asset And Lease Liability (Tables)	6 Months Ended
	Jun. 30, 2021
Right-of-use Asset And Lease Liability
SCHEDULE OF COMPONENTS OF LEASE EXPENSE	The components of lease expense, which are included in other general and administrative expense, for the three months and six months ended June 30, 2021 and 2020, respectively, are as follows: SCHEDULE OF COMPONENTS OF LEASE EXPENSE Three Months Ended June 30, Six Months Ended June 30, 2021 2020 2021 2020 Operating lease expense $ 75,058 $ 151,464 $ 183,650 $ 302,028
SCHEDULE OF CASH PAID FOR AMOUNTS INCLUDED THE MEASUREMENT OF LEASE LIABILITIES	Cash paid for amounts included in the measurement of lease liabilities for the three months and six months ended June 30, 2021 and 2020, respectively, are as follows: SCHEDULE OF CASH PAID FOR AMOUNTS INCLUDED THE MEASUREMENT OF LEASE LIABILITIES Three Months Ended June 30, Six Months Ended June 30, 2021 2020 2021 2020 Operating cash flows from operating leases $ 75,058 $ 151,464 $ 183,650 $ 302,028
SCHEDULE OF SUPPLEMENTAL BALANCE SHEET AND OTHER INFORMATION	Supplemental balance sheet and other information related to operating leases are as follows: SCHEDULE OF SUPPLEMENTAL BALANCE SHEET AND OTHER INFORMATION June 30, 2021 December 31, 2020 Operating leases right-of-use assets $ 183,685 $ 278,552 Lease liability, current portion 90,276 139,189 Lease liability, net of current portion 111,096 157,050 Total operating lease liabilities $ 201,372 $ 296,239 Weighted average remaining lease term 2.17 2.32 Weighted average discount rate 10.73 % 10.31 %
SCHEDULE OF MATURITIES OF LEASE LIABILITIES	Future maturities of operating lease liabilities as of June 30, 2021 are as follows: SCHEDULE OF MATURITIES OF LEASE LIABILITIES Operating leases Remainder of 2021 $ 50,752 2022 102,891 2023 69,333 Total lease payments 222,976 Less: Interest (21,604 ) Total lease liability $ 201,372

Property And Equipment (Tables)

Property And Equipment (Tables)	6 Months Ended
	Jun. 30, 2021
Property, Plant and Equipment [Abstract]
SCHEDULE OF PROPERTY AND EQUIPMENT	Property and equipment, net, consists of the following: SCHEDULE OF PROPERTY AND EQUIPMENT Useful Life June 30, 2021 December 31, 2020 Furniture and fixtures 5 7 $ 96,185 $ 231,222 Computers and software 3 7 213,660 246,323 Leasehold improvements 15 40,130 155,583 349,975 633,128 Less: accumulated depreciation (309,331 ) (493,953 ) Total $ 40,644 $ 139,175

Equity Transactions (Tables)

Equity Transactions (Tables)	6 Months Ended
	Jun. 30, 2021
Equity [Abstract]
SCHEDULE OF ASSUMPTIONS USED TO CALCULATE FAIR VALUE OF STOCK OPTIONS	Inputs used in the valuation models are as follows: SCHEDULE OF ASSUMPTIONS USED TO CALCULATE FAIR VALUE OF STOCK OPTIONS 2021 Grants Option value $ 0.054 to $ 0.056 Risk Free Rate 0.90 % to 1.37 % Expected Dividend- yield - to - Expected Volatility 173.99 % to 176.04 % Expected term (years) 5 to 7
SUMMARY OF STOCK OPTION ACTIVITY	The following is a summary of stock option activity for the six months ended June 30, 2020 and 2021: SUMMARY OF STOCK OPTION ACTIVITY Shares Weighted Average Exercise Price Weighted Average Remaining Term (Years) Outstanding at December 31, 2019 425,000 $ 1.38 7.71 Granted — — — Expired/Cancelled (15,000 ) 1.35 — Outstanding and exercisable at June 30, 2020 410,000 $ 1.39 7.23 Outstanding at December 31, 2020 410,000 $ 1.39 6.72 Granted 54,750,000 0.07 9.75 Expired/Cancelled (25,000 ) 2.16 — Outstanding at June 30, 2021 55,135,000 $ 0.08 9.73 Exercisable at June 30, 2021 5,718,333 $ 0.16 9.52
SUMMARY OF STOCK OPTION ACTIVITY NON-VESTED	The following is a summary of the Company’s non-vested shares for the six months ended June 30, 2021: SUMMARY OF STOCK OPTION ACTIVITY NON-VESTED Shares Weighted Average Grant Date Fair Value Non-vested at December 31, 2020 - $ - Granted 54,750,000 0.06 Vested (5,333,333 ) 0.05 Forfeited - - Non-vested at June 30, 2021 49,416,667 $ 0.06
SCHEDULE OF ANTIDILUTIVE SECURITIES OF BASIC AND DILUTED NET LOSS PER SHARE	The Company excluded the following securities from the calculation of basic and diluted net loss per share as the effect would have been antidilutive: SCHEDULE OF ANTIDILUTIVE SECURITIES OF BASIC AND DILUTED NET LOSS PER SHARE For the Six Months Ended June 30, 2021 2020 Options to purchase common stock (in the money) 4,977,273 410,000 Warrants to purchase common stock (in the money) 386,908,082 404,821,082 Series A Preferred Stock convertible to common stock 520,305,884 - Series B & D Preferred Stock convertible to common stock - 38,308,600 Total 912,191,239 443,539,682

Derivative Liabilities (Tables)

Derivative Liabilities (Tables)	6 Months Ended
	Jun. 30, 2021
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
SCHEDULE OF FAIR VALUE, LIABILITIES MEASURED ON RECURRING BASIS	The following are rollforwards of the liabilities during the six months ended June 30, 2020: SCHEDULE OF FAIR VALUE, LIABILITIES MEASURED ON RECURRING BASIS Derivative Liability - Warrants Balance at December 31, 2019 $ 315,855 Series D Warrant reclass from equity to liability 509,764 Warrants issued with modification of Horne Note 198,994 Warrants issued with April 17, 2020 financing 6,148,816 Fair value adjustments 2,882,247 Balance at June 30, 2020 $ 10,055,676 Redemption Put Liability Balance at December 31, 2019 $ 267,399 Issuance of Series D Convertible Preferred Stock 5,306 Fair value adjustments (174,707 ) Balance at June 30, 2020 $ 97,998
Derivative Liability- Warrants [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
SCHEDULE OF ASSUMPTIONS FOR WARRANTS	The Company estimated the fair value of the warrant derivative liability as of June 30, 2020 using the following assumptions: SCHEDULE OF ASSUMPTIONS FOR WARRANTS June 30, 2020 Fair value of underlying stock $ 0.05 Exercise price $ 0.014 Risk free rate 0.14 0.66 % Expected term (in years) 0.17 10.27 Stock price volatility 109 312 % Expected dividend yield —
Redemption Liability [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
SCHEDULE OF ASSUMPTIONS FOR WARRANTS	SCHEDULE OF ASSUMPTIONS FOR WARRANTS June 30, 2020 Fair value of underlying stock $ 0.05 Exercise price $ 0.20409 Risk free rate 0.66 % Expected term (in years) 9.5 Stock price volatility 107 % Expected dividend yield —

Common Stock Warrants (Tables)

Common Stock Warrants (Tables)	6 Months Ended
	Jun. 30, 2021
Common Stock Warrants
SUMMARY OF WARRANT ACTIVITY	A summary of the Company’s warrant issuance activity and related information for the period ended June 30, 2021 and 2020 is as follows: SUMMARY OF WARRANT ACTIVITY Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Life Outstanding and exercisable at December 31, 2019 44,806,076 $ 0.78 4.59 Issued 5,178,720 0.015 9.79 Outstanding and exercisable at June 30, 2020 49,984,796 $ 0.104 9.16 Issued, not yet exercisable (1) 354,836,286 0.014 9.79 Total outstanding at June 30, 2020 404,821,082 0.104 9.16 Outstanding and exercisable at December 31, 2020 413,423,972 $ 0.015 10.30 Expired (3,366,520 ) $ 0.32 — Issued — — — Total outstanding and exercisable at June 30, 2021 410,057,452 $ 0.63 8.63
SCHEDULE OF ASSUMPTIONS FOR WARRANTS	SCHEDULE OF ASSUMPTIONS FOR WARRANTS Event Description Date Number of Warrants H-CYTE Stock Price Exercise Price of Warrant Grant Date Fair Value Life of Warrant Risk Free Rate of Return (%) Annualized Volatility Rate (%) Short-term note, related party 1/13/2020 268,571 $ 0.12 $ 0.75 $ 0.07 3 1.60 145.76 Private placement of Series D Convertible Preferred Stock 1/17/2020 244,996 $ 0.15 $ 0.75 $ 0.13 10 1.84 144.30 Granted for bridge financing 4/8/2020 296,875 $ 0.05 $ 0.40 $ 0.04 3 0.34 131.82 Short-term note, related party conversion 4/17/2020 4,368,278 $ 0.05 $ 0.014 $ 0.05 10 0.65 100.64 Granted for bridge financing 9/11/2020 364,439,176 $ 0.05 $ 0.014 $ 0.017 10 0.65 96.97

Description of the Company (Det

Description of the Company (Details Narrative)	6 Months Ended
	Jun. 30, 2021	Sep. 11, 2020
FWHC, LLC [Member]
Entity Listings [Line Items]
Equity method investment, ownership percentage		61.00%
Rion LLC [Member] | Product Supply Agreement [Member]
Entity Listings [Line Items]
Agreement term	10 years

Liquidity, Going Concern and _2

Liquidity, Going Concern and Management’s Plans (Details Narrative) - USD ($)	Apr. 02, 2021	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Aug. 11, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Net loss		$ 2,058,005	$ 6,432,336	$ 3,465,679	$ 8,848,564
Proceeds from convertible debt				1,070,118
Cash on hand		$ 1,516,000		$ 1,516,000
Subsequent Event [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Cash on hand						$ 1,099,000
Secured Convertible Note Purchase Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Debt principal amount	$ 2,575,000
Debt instrument, maturity date	Mar. 31, 2022
Debt interest rate	8.00%
Debt instrument conversion discount price percentage	20.00%
Secured Convertible Note Purchase Agreement [Member] | FWHC Bridge, LLC [Member] | Investor [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Proceeds from convertible debt	$ 1,500,000
Secured Convertible Note Purchase Agreement [Member] | FWHC [Member] | Investor [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Proceeds from convertible debt	$ 25,000

SCHEDULE OF COMPONENTS OF LEASE

SCHEDULE OF COMPONENTS OF LEASE EXPENSE (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Right-of-use Asset And Lease Liability
Operating lease expense	$ 75,058	$ 151,464	$ 183,650	$ 302,028

SCHEDULE OF CASH PAID FOR AMOUN

SCHEDULE OF CASH PAID FOR AMOUNTS INCLUDED THE MEASUREMENT OF LEASE LIABILITIES (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Right-of-use Asset And Lease Liability
Operating cash flows from operating leases	$ 75,058	$ 151,464	$ 183,650	$ 302,028

SCHEDULE OF SUPPLEMENTAL BALANC

SCHEDULE OF SUPPLEMENTAL BALANCE SHEET AND OTHER INFORMATION (Details) - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Right-of-use Asset And Lease Liability
Operating leases right-of-use assets	$ 183,685	$ 278,552
Lease liability, current portion	90,276	139,189
Lease liability, net of current portion	111,096	157,050
Total operating lease liabilities	$ 201,372	$ 296,239
Weighted average remaining lease term	2 years 2 months 1 day	2 years 3 months 25 days
Weighted average discount rate	10.73%	10.31%

SCHEDULE OF MATURITIES OF LEASE

SCHEDULE OF MATURITIES OF LEASE LIABILITIES (Details) - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Right-of-use Asset And Lease Liability
Remainder of 2021	$ 50,752
2022	102,891
2023	69,333
Total lease payments	222,976
Less: Interest	(21,604)
Total lease liability	$ 201,372	$ 296,239

Right-of-use Asset And Lease _3

Right-of-use Asset And Lease Liability (Details Narrative) - Tampa, FL [Member] - USD ($)	Apr. 02, 2021	Aug. 02, 2021
SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate [Line Items]
Lease, description	The Company did not renew its corporate office space lease in Tampa, FL which expired on March 31, 2021. The Company leases medical clinic space in Tampa, FL, Nashville, TN, and Scottsdale, AZ. These clinic locations have various expiration dates through August 31, 2023. The leasing arrangements contain various renewal options that are adjusted for increases in the consumer price index or agreed upon rates. The Company entered into a twelve-month lease for its Tampa location beginning April 1, 2021 totalling $71,775. The Dallas, TX lease expired on July 31, 2020 and the Pittsburgh, PA lease expired on October 31, 2020, neither of which were renewed as these clinic locations were permanently closed.
Short-term lease commitment, amount		$ 71,775

SCHEDULE OF PROPERTY AND EQUIPM

SCHEDULE OF PROPERTY AND EQUIPMENT (Details) - USD ($)	6 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Property and equipment	$ 349,975	$ 633,128
Less: accumulated depreciation	(309,331)	(493,953)
Property and Equipment, net	40,644	139,175
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	$ 96,185	231,222
Furniture and Fixtures [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Useful Life	5 years
Furniture and Fixtures [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Useful Life	7 years
Computers and Software [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	$ 213,660	246,323
Computers and Software [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Useful Life	3 years
Computers and Software [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Useful Life	7 years
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Useful Life	15 years
Property and equipment	$ 40,130	$ 155,583

Property And Equipment (Details

Property And Equipment (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 2,000	$ 17,000	$ 14,000	$ 39,000
Loss on disposal of assets	$ 93,000		$ 93,000

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	Apr. 02, 2021	Jan. 12, 2021	Oct. 02, 2020	Sep. 11, 2020	Jul. 28, 2020	Mar. 25, 2020	Feb. 01, 2019	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Related Party Transaction [Line Items]
Proceeds from convertible debt										$ 1,070,118
Series A Preferred Stock [Member]
Related Party Transaction [Line Items]
Conversion of stock, shares issued				117,362,143
Series A Preferred Stock [Member] | Promissory Notes from April 2020 [Member]
Related Party Transaction [Line Items]
Conversion of stock, shares issued				123,031,819
Series A Preferred Stock [Member] | April Secured Note [Member]
Related Party Transaction [Line Items]
Conversion of stock, shares issued				75,162,429
Series A Preferred Stock [Member] | Hawes Notes [Member]
Related Party Transaction [Line Items]
Conversion of stock, shares issued				35,860,079
FWHC HOLDINGS, LLC [Member]
Related Party Transaction [Line Items]
Percentage of fully diluted shares owned				61.00%
Warrants issued				273,356,676
Warrant term				10 years
Warrants exercise price, per share				$ 0.014
FWHC HOLDINGS, LLC [Member] | Series D Convertible Preferred Stock [Member]
Related Party Transaction [Line Items]
Conversion of stock, shares issued					15,518,111
Mr. Raymond Monteleone [Member]
Related Party Transaction [Line Items]
Officers compensation								$ 17,500	$ 17,500	35,000	47,500
Oral Consulting Agreement [Member]
Related Party Transaction [Line Items]
Advisory service fee						$ 5,000
Audit fees						$ 2,500
Oral Consulting Agreement [Member] | Mr. Raymond Monteleone [Member]
Related Party Transaction [Line Items]
Advisory service fee							$ 10,000
Audit fees		$ 5,000					$ 5,000
Amounts receives per month		4,167
Oral Consulting Agreement [Member] | Michael Yurkowsky [Member]
Related Party Transaction [Line Items]
Audit fees			$ 4,167
Officers compensation								12,500	0	25,000	0
Oral Consulting Agreement [Member] | Mr. William Horne [Member]
Related Party Transaction [Line Items]
Audit fees		$ 4,167
Officers compensation								$ 12,500	$ 0	$ 17,000	$ 0
Secured Convertible Note Purchase Agreement [Member]
Related Party Transaction [Line Items]
Debt principal amount	$ 2,575,000
Debt instrument, maturity date	Mar. 31, 2022
Debt instrument, interest rate	8.00%
Debt instrument conversion discount price percentage	20.00%
Secured Convertible Note Purchase Agreement [Member] | FWHC Bridge, LLC [Member] | Investor [Member]
Related Party Transaction [Line Items]
Proceeds from convertible debt	$ 1,500,000
Secured Convertible Note Purchase Agreement [Member] | FWHC [Member] | Investor [Member]
Related Party Transaction [Line Items]
Proceeds from convertible debt	$ 25,000

SCHEDULE OF ASSUMPTIONS USED TO

SCHEDULE OF ASSUMPTIONS USED TO CALCULATE FAIR VALUE OF STOCK OPTIONS (Details) - 2021 Grants [Member]	6 Months Ended
	Jun. 30, 2021$ / shares
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Option value	$ 0.054
Risk-free interest rates	0.90%
Dividend yield
Volatility	173.99%
Expected life (in years)	5 years
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Option value	$ 0.056
Risk-free interest rates	1.37%
Dividend yield
Volatility	176.04%
Expected life (in years)	7 years

SUMMARY OF STOCK OPTION ACTIVIT

SUMMARY OF STOCK OPTION ACTIVITY (Details) - $ / shares	6 Months Ended		12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Equity [Abstract]
Number of Shares Options Outstanding Beginning Balance	410,000	425,000	425,000
Weighted Average Exercise Price Outstanding Beginning Balance	$ 1.39	$ 1.38	$ 1.38
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term	9 years 8 months 23 days	7 years 2 months 23 days	6 years 8 months 19 days	7 years 8 months 15 days
Number of Options Granted	54,750,000
Weighted Average Exercise Price Granted	$ 0.07	$ 0
Number of Options Expired/Cancelled	(25,000)	(15,000)
Weighted Average Exercise Price Expired/ Cancelled	$ 2.16	$ 1.35
Number of Shares Options Outstanding and exercisable Ending Balance	5,718,333	410,000
Weighted Average Exercise Price Outstanding and exercisable Ending Balance	$ 0.08	$ 1.39
[custom:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm]	9 years 9 months
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance	55,135,000		410,000	425,000
Options Exercisable	5,718,333	410,000
Weighted average exercise price, Exercisable	$ 0.16
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term	9 years 6 months 7 days

SUMMARY OF STOCK OPTION ACTIV_2

SUMMARY OF STOCK OPTION ACTIVITY NON-VESTED (Details)	6 Months Ended
	Jun. 30, 2021$ / sharesshares
Equity [Abstract]
Non-vested, Shares, Outstanding beginning balance | shares
Non-vested, Weighted Average Grant Date Fair Value, Outstanding beginning balance | $ / shares
Non-vested, Shares, Outstanding beginning balance | shares	54,750,000
Non-vested, Weighted Average Grant Date Fair Value, Outstanding beginning balance | $ / shares	$ 0.06
Non-vested, Shares, Outstanding beginning balance | shares	(5,333,333)
Non-vested, Weighted Average Grant Date Fair Value, Outstanding beginning balance | $ / shares	$ 0.05
Non-vested, Shares, Outstanding beginning balance | shares
Non-vested, Weighted Average Grant Date Fair Value, Outstanding beginning balance | $ / shares
Non-vested, Shares, Outstanding beginning balance | shares	49,416,667
Non-vested, Weighted Average Grant Date Fair Value, Outstanding beginning balance | $ / shares	$ 0.06

SCHEDULE OF ANTIDILUTIVE SECURI

SCHEDULE OF ANTIDILUTIVE SECURITIES OF BASIC AND DILUTED NET LOSS PER SHARE (Details) - shares	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities (in shares)	912,191,239	443,539,682
Stock Options Outstanding [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities (in shares)	4,977,273	410,000
Warrants to Purchase Common Stock [Member[
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities (in shares)	386,908,082	404,821,082
Series A Preferred Stock Convertible to Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities (in shares)	520,305,884
Series A & D Preferred Stock Convertible to Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities (in shares)		38,308,600

Equity Transactions (Details Na

Equity Transactions (Details Narrative) - USD ($)	Apr. 02, 2021	Sep. 24, 2020	Jul. 28, 2020	Apr. 23, 2020	Feb. 29, 2020	Jun. 30, 2021	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020	Dec. 31, 2019	Jul. 29, 2020
Accumulated Other Comprehensive Income (Loss) [Line Items]
Value of shares issued for services								$ 35,000
Common stock, shares authorized						1,600,000,000	1,600,000,000		1,600,000,000		1,600,000,000
Preferred stock, shares authorized						1,000,000,000	1,000,000,000		1,000,000,000		1,000,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures							54,750,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price							$ 0.07	$ 0
Stock option expiration term							10 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number						55,135,000	55,135,000		410,000	425,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares							5,333,333
Share-based Payment Arrangement, Expense							$ 862,000	$ 643
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term							9 years 8 months 23 days	7 years 2 months 23 days	6 years 8 months 19 days	7 years 8 months 15 days
Management fee							$ 0	$ 0
Anti-dilutive securities (in shares)							912,191,239	443,539,682
Minimum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants exercise price, per share						$ 0.08	$ 0.08
Warrants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Anti-dilutive securities (in shares)							23,149,370
Stock Options [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Anti-dilutive securities (in shares)							385,000
Share-based Payment Arrangement [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number						55,135,000	55,135,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares							5,718,133
Share-based Payment Arrangement, Expense							$ 862,000
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount						$ 2,150,000	$ 2,150,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term							3 years 2 months 26 days
Directors and Officers [Member] | Secured Convertible Note Purchase Agreement [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures	54,750,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$ 0.07
Directors and Officers [Member] | Secured Convertible Note Purchase Agreement [Member] | Immediately Vested [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures	4,750,000
Series A Preferred Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Value of shares issued for services
Share issued price per share		$ 0.014
Preferred stock, shares authorized						800,000,000	800,000,000		800,000,000		800,000,000
Stock issued during period new issue shares		15,235,381
Number of shares converted						8,123,691	17,803,525
Common stock conversion ratio							common stock at a 1:1 ratio
Series A Preferred Stock [Member] | Outstanding Promissory Note [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stock issued during period new issue shares		323,844,416
Principal amount and accrued interest		$ 4,483,617
Series A Preferred Stock [Member] | Purchasers [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stock issued during period new issue shares		203,049,643
Proceeds from offering		$ 3,055,985
Series B and Series D Preferred Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stock conversion shares issued			17,893,076
LilyCon Investments, LLC [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Value of shares issued for services					$ 35,000
Share issued price per share					$ 0.32
Number of shares issued for services					109,375
Home Management LLC [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Debt conversion of common stock shares				4,368,278
Warrant term				10 years
Debt conversion price per share				$ 0.014
Warrants exercise price, per share				$ 0.05

Commitments & Contingencies (De

Commitments & Contingencies (Details Narrative) - USD ($)	Oct. 09, 2019	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Guaranteed payments		$ 26,000	$ 0	$ 43,000	$ 22,000
Research and development expense			200,000		950,000
Rion Agreement [Member] | Rion LLC [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Expenses incurred upon achievement of milestones	$ 350,000
Research and development expense			$ 200,000	$ 0	$ 950,000

Short-term Debt (Details Narrat

Short-term Debt (Details Narrative) - USD ($)	Apr. 02, 2021	Apr. 29, 2020	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2019	Dec. 31, 2020	Apr. 09, 2020	Mar. 31, 2020	Mar. 27, 2020
Short-term Debt [Line Items]
Common stock, par value			$ 0.001		$ 0.001			$ 0.001
Proceeds from Convertible Debt					$ 1,070,118
Interest Expense			$ 54,145	$ 363,023	$ 59,930	$ 419,172
Investor [Member]
Short-term Debt [Line Items]
Notes payable									$ 500,000		$ 500,000
Third Noteholder [Member]
Short-term Debt [Line Items]
Notes payable										$ 300,000
Fees and penalties										85,000
Accrued interest										40,000
Debt principal amount										$ 424,615
Convertible Notes Payable Related Parties [Member]
Short-term Debt [Line Items]
Interest Expense			29,220
Convertible Notes Payable [Member]
Short-term Debt [Line Items]
Interest Expense			20,118
Notes Payable [Member] | Merger [Member]
Short-term Debt [Line Items]
Debt description					The Company finalized an eighteen-month extension to March 1, 2021
Accrued interest			$ 5,000		$ 5,000
Debt Instrument, Maturity Date					Aug. 1, 2019
Debt Instrument, Interest Rate, Stated Percentage			5.00%		5.00%
Debt Instrument, Periodic Payment, Principal					$ 5,800
Promissory Notes [Member]
Short-term Debt [Line Items]
Notes payable								$ 67,000
New Principal Amount [Member] | Investor [Member]
Short-term Debt [Line Items]
Notes payable									$ 1,000,000
Securities Purchase Agreement [Member] | Accredited Investors [Member]
Short-term Debt [Line Items]
Number of common stock shares sold, value					$ 750,000
Sale of stock price per share			$ 50,000		$ 50,000
Debt description					Each Unit consists of (i) a 12% senior secured convertible note, initially convertible into shares of the Company’s common stock, par value $0.001 per share, at a conversion price equal to the lesser of $0.40 or ninety percent (90%) of the per share purchase price of any shares of common stock or common stock equivalents issued in future private placements of equity and/or debt securities completed by the Company following this offering, and (ii) a three-year warrant to purchase such number of shares of the Company’s common stock equal to one hundred percent (100%) of the number of shares of common stock issuable upon conversion of the notes at $0.40.
Conversion of common stock, percentage					12.00%
Common stock, par value			0.001		$ 0.001
Market value of common stock			$ 0.40		$ 0.40
Warrant term			3 years		3 years
Debt converted into shares, value							$ 100,000
Redeemed convertible notes value							$ 350,000
Secured Convertible Note Purchase Agreement [Member]
Short-term Debt [Line Items]
Debt principal amount	$ 2,575,000
Debt Instrument, Maturity Date	Mar. 31, 2022
Debt Instrument, Interest Rate, Stated Percentage	8.00%
Debt instrument conversion discount price percentage	20.00%
Secured Convertible Note Purchase Agreement [Member] | FWHC Bridge, LLC [Member] | Investor [Member]
Short-term Debt [Line Items]
Proceeds from Convertible Debt	$ 1,500,000
Secured Convertible Note Purchase Agreement [Member] | FWHC [Member] | Investor [Member]
Short-term Debt [Line Items]
Proceeds from Convertible Debt	$ 25,000
Payroll Protection Program [Member]
Short-term Debt [Line Items]
Debt principal amount		$ 809,082
Amount forgiven to non-payroll costs, percentage		40.00%

SCHEDULE OF FAIR VALUE, LIABILI

SCHEDULE OF FAIR VALUE, LIABILITIES MEASURED ON RECURRING BASIS (Details)	6 Months Ended
	Jun. 30, 2020USD ($)
Derivative Liability- Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Beginning balance, Derivative Liability- Warrants	$ 315,855
Series D Warrant reclass from equity to liability	509,764
Warrants issued with modification of Horne Note	198,994
Warrants issued with April 17, 2020 financing	6,148,816
Fair value adjustments	2,882,247
Ending balance, Derivative Liability- Warrants	10,055,676
Redemption Put Liability [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Beginning balance. Redemption Put Liability	267,399
Issuance of Series D Convertible Preferred Stock	5,306
Fair value adjustments	(174,707)
Ending balance	$ 97,998

SCHEDULE OF ASSUMPTIONS FOR WAR

SCHEDULE OF ASSUMPTIONS FOR WARRANTS (Details)	6 Months Ended
	Jun. 30, 2021$ / sharesshares	Jun. 30, 2020$ / shares
Private Placement of Series D Convertible Preferred Stock 1/18/2020 [Member]
Derivative [Line Items]
Number of Warrants | shares	244,996
H-CYTE Stock Price	$ 0.15
Warrants exercise price, per share	0.75
Warrant Grant Date Fair Value	$ 0.13
Life of Warrant	10 years
Granted for Bridge Financing 04/08/2020 [Member]
Derivative [Line Items]
Number of Warrants | shares	296,875
H-CYTE Stock Price	$ 0.05
Warrants exercise price, per share	0.40
Warrant Grant Date Fair Value	$ 0.04
Life of Warrant	3 years
Short Term Note, Related Party Conversion 04/17/2020 [Member]
Derivative [Line Items]
Number of Warrants | shares	4,368,278
H-CYTE Stock Price	$ 0.05
Warrants exercise price, per share	0.014
Warrant Grant Date Fair Value	$ 0.05
Life of Warrant	10 years
Granted for Bridge Financing 04/17/2020 [Member]
Derivative [Line Items]
Number of Warrants | shares	364,439,176
H-CYTE Stock Price	$ 0.05
Warrants exercise price, per share	0.014
Warrant Grant Date Fair Value	$ 0.017
Life of Warrant	10 years
Short-term Note Related Party 1/13/2020 [Member]
Derivative [Line Items]
Number of Warrants | shares	268,571
H-CYTE Stock Price	$ 0.12
Warrants exercise price, per share	0.75
Warrant Grant Date Fair Value	$ 0.07
Life of Warrant	3 years
Minimum [Member]
Derivative [Line Items]
Warrants exercise price, per share	$ 0.08
Measurement Input, Risk Free Interest Rate [Member] | Granted for Bridge Financing 04/08/2020 [Member]
Derivative [Line Items]
Warrant Input, Percentage	0.0034
Measurement Input, Risk Free Interest Rate [Member] | Short Term Note, Related Party Conversion 04/17/2020 [Member]
Derivative [Line Items]
Warrant Input, Percentage	0.0065
Measurement Input, Risk Free Interest Rate [Member] | Granted for Bridge Financing 04/17/2020 [Member]
Derivative [Line Items]
Warrant Input, Percentage	0.0065
Measurement Input, Risk Free Interest Rate [Member] | Short-term Note Related Party 1/13/2020 [Member]
Derivative [Line Items]
Warrant Input, Percentage	0.0160
Measurement Input, Price Volatility [Member] | Private Placement of Series D Convertible Preferred Stock 1/18/2020 [Member]
Derivative [Line Items]
Warrant Input, Percentage	1.4430
Measurement Input, Price Volatility [Member] | Granted for Bridge Financing 04/08/2020 [Member]
Derivative [Line Items]
Warrant Input, Percentage	1.3182
Measurement Input, Price Volatility [Member] | Short Term Note, Related Party Conversion 04/17/2020 [Member]
Derivative [Line Items]
Warrant Input, Percentage	1.0064
Measurement Input, Price Volatility [Member] | Granted for Bridge Financing 04/17/2020 [Member]
Derivative [Line Items]
Warrant Input, Percentage	0.9697
Measurement Input, Price Volatility [Member] | Short-term Note Related Party 1/13/2020 [Member]
Derivative [Line Items]
Warrant Input, Percentage	1.4576
Measurement Input, Expected Dividend Rate [Member] | Private Placement of Series D Convertible Preferred Stock 1/18/2020 [Member]
Derivative [Line Items]
Warrant Input, Percentage	0.0184
Derivative Liability- Warrants [Member] | Fair Value of Underlying Stock [Member]
Derivative [Line Items]
Derivative Liability, Measurement Input		0.05
Derivative Liability- Warrants [Member] | Measurement Input, Exercise Price [Member]
Derivative [Line Items]
Derivative Liability, Measurement Input		0.014
Derivative Liability- Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member]
Derivative [Line Items]
Derivative Liability, Measurement Input		0.0014
Derivative Liability- Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member]
Derivative [Line Items]
Derivative Liability, Measurement Input		0.0066
Derivative Liability- Warrants [Member] | Measurement Input, Expected Term [Member] | Minimum [Member]
Derivative [Line Items]
Derivative Liability, Measurement Input, term		2 months 1 day
Derivative Liability- Warrants [Member] | Measurement Input, Expected Term [Member] | Maximum [Member]
Derivative [Line Items]
Derivative Liability, Measurement Input, term		10 years 3 months 7 days
Derivative Liability- Warrants [Member] | Measurement Input, Price Volatility [Member] | Minimum [Member]
Derivative [Line Items]
Derivative Liability, Measurement Input		1.09
Derivative Liability- Warrants [Member] | Measurement Input, Price Volatility [Member] | Maximum [Member]
Derivative [Line Items]
Derivative Liability, Measurement Input		3.12
Derivative Liability- Warrants [Member] | Measurement Input, Expected Dividend Rate [Member]
Derivative [Line Items]
Derivative Liability, Measurement Input		0
Redemption Put Liability [Member] | Fair Value of Underlying Stock [Member]
Derivative [Line Items]
Derivative Liability, Measurement Input		0.05
Redemption Put Liability [Member] | Measurement Input, Exercise Price [Member]
Derivative [Line Items]
Derivative Liability, Measurement Input		0.20409
Redemption Put Liability [Member] | Measurement Input, Risk Free Interest Rate [Member]
Derivative [Line Items]
Derivative Liability, Measurement Input		0.0066
Redemption Put Liability [Member] | Measurement Input, Expected Term [Member]
Derivative [Line Items]
Derivative Liability, Measurement Input, term		9 years 6 months
Redemption Put Liability [Member] | Measurement Input, Price Volatility [Member]
Derivative [Line Items]
Derivative Liability, Measurement Input		1.07
Redemption Put Liability [Member] | Measurement Input, Expected Dividend Rate [Member]
Derivative [Line Items]
Derivative Liability, Measurement Input		0

Derivative Liabilities (Details

Derivative Liabilities (Details Narrative)	Apr. 23, 2020USD ($)$ / sharesshares	Jun. 30, 2021USD ($)$ / sharesshares	Jun. 30, 2021USD ($)$ / sharesshares	Jun. 30, 2020USD ($)
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]
Fair value of warrants				$ 2,707,541
Proceeds from Issuance of Warrants				$ 3,842,695
Fair value of warrants			$ 73,000
[custom:RedemptionPutLiabilityDescription]			The fair market value of the redemption put liability at inception was approximately $
[custom:FairValueOfRedemptionPut]			$ 614,000
Other Operating Income (Expense) [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]
Remeasured value change in fair value of derivative		$ 3,057,225	2,882,247
Other Operating Income (Expense) [Member] | Redemption Put Liability [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]
Remeasured value change in fair value of derivative		$ 19,000	$ 175,000
Home Management LLC [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]
Warrants exercise price, per share | $ / shares	$ 0.05
Number of shares issued on conversion | shares	4,368,278
Warrant term	10 years
Fair value of warrants	$ 199,000
Home Management LLC [Member] | Measurement Input, Exercise Price [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]
Warrants measurement input | $ / shares	0.014
Home Management LLC [Member] | Measurement Input, Price Volatility [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]
Warrants measurement input	1.01
Home Management LLC [Member] | Measurement Input, Risk Free Interest Rate [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]
Warrants measurement input	0.0065
Series B Warrants [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]
Warrants to purchase common stock | shares		403,125	403,125
Fair value of warrants			$ 75,000
Warrant description			In conjunction with the Series D Preferred financing (see note 12), the Company offered the Series B warrant holders the option to exchange their warrants on the basis of 1 warrant for 0.40 common shares.
Warrants | shares		1,007,813	1,007,813
Series B Warrants [Member] | April 2020 Offering [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]
Fair value of the derivative liability		$ 75,000	$ 75,000
Series D Warrants [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]
Warrants to purchase common stock | shares		14,669,757	14,669,757
Warrants exercise price, per share | $ / shares		$ 0.75	$ 0.75
Series D Warrants [Member] | Fair Value Before and After Modification [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]
Fair value of the derivative liability		$ 510,000	$ 510,000
April Bridge Loan and Converted Advance Warrants [Member] | April 2020 Offering [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]
Warrant term		10 years	10 years
Warrant description			The April Offering entitled the investors to warrants with the right to purchase up to 100% of the aggregate number of shares of Common Stock into which the Purchaser’s Note may ultimately be converted. The Company also received a $1,000,000 advance which was converted into a Converted Advance Note and Converted Advance Warrants in April 2020. The Converted Advance Warrants entitle the holder to purchase up to 200% of the aggregate number of shares of Common Stock into which the Converted Advanced Note may ultimately be converted.
Proceeds from Issuance of Warrants			$ 2,842,695
[custom:AdvanceNotePayable-0]		$ 1,000,000	$ 1,000,000
April Bridge Loan and Converted Advance Warrants [Member] | April 2020 Offering [Member] | Measurement Input, Exercise Price [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]
Warrants measurement input | $ / shares		0.014	0.014
April Bridge Loan and Converted Advance Warrants [Member] | April 2020 Offering [Member] | Measurement Input, Price Volatility [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]
Warrants measurement input		1.03	1.03
April Bridge Loan and Converted Advance Warrants [Member] | April 2020 Offering [Member] | Measurement Input, Risk Free Interest Rate [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]
Warrants measurement input		0.0065	0.0065
April Bridge Loan and Converted Advance Warrants [Member] | April 2020 Offering [Member] | Measurement Input, Trading Market [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]
Warrants exercise price, per share | $ / shares		$ 0.05	$ 0.05
April Bridge Loan and Converted Advance Warrants [Member] | April 2020 Offering [Member] | Exercise of Purchaser Warrants [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]
Fair value of warrants			$ 3,279,000
Number of shares issuable upon exercise of warrants, shares | shares			203,050,000
April Bridge Loan and Converted Advance Warrants [Member] | April 2020 Offering [Member] | Converted Advance Warrants [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]
Fair value of warrants			$ 2,869,300
Number of shares issuable upon exercise of warrants, shares | shares			142,857,000

SUMMARY OF WARRANT ACTIVITY (De

SUMMARY OF WARRANT ACTIVITY (Details) - $ / shares		6 Months Ended
		Jun. 30, 2021	Jun. 30, 2020
Common Stock Warrants
Number of Shares, Warrants Outstanding and Exercisable, Beginning		413,423,972	44,806,076
Weighted Average Exercise Price Outstanding and Exercisable, Beggining		$ 0.015	$ 0.78
Weighted Average Remaining Contractual Life Warrants Outstanding and Exercisable, Beginning		10 years 3 months 18 days	4 years 7 months 2 days
Number of Shares, Warrants Issued		0	5,178,720
Weighted Average Exercise Price Warrants Issued		$ 0	$ 0.015
Weighted Average Exercise Price Warrants Issued			9 years 9 months 14 days
Number of Shares, Warrants Outstanding and Exercisable, Ending		410,057,452	49,984,796
Weighted Average Exercise Price Outstanding and Exercisable, Ending		$ 0.63	$ 0.104
Weighted Average Remaining Contractual Life Warrants Outstanding and Exercisable, Ending		8 years 7 months 17 days	9 years 1 month 28 days
Number of Shares, Warrants Issued, not yet exercisable	[1]		354,836,286
Weighted Average Exercise Price Warrants Issued, not yet exercisable	[1]		$ 0.014
Weighted Average Exercise Price Warrants Issued, not yet exercisable			9 years 9 months 14 days
Number of Shares, Warrants Outstanding, Ending			404,821,082
Weighted Average Exercise Price Outstanding Ending			$ 0.104
Weighted Average Remaining Contractual Life Warrants Outstanding, Ending			9 years 1 month 28 days
Number of Shares, Warrants Expired		(3,366,520)
Weighted Average Exercise Price Warrants Expired		$ 0.32
[1]	The Company had estimated on June 30, 2020 that the number of warrants to be granted for the bridge financing would be 354,836,286 9,602,890 364,439,176 1,292,411

Common Stock Warrants (Details

Common Stock Warrants (Details Narrative) - shares	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Class of Warrant or Right [Line Items]
Anti-dilutive securities (in shares)	912,191,239	443,539,682
Series B Preferred Shareholders [Member]
Class of Warrant or Right [Line Items]
Anti-dilutive securities (in shares)	1,292,411
Bridge Financing [Member]
Class of Warrant or Right [Line Items]
Number of warrants to be granted		354,836,286
Additional number of warrants issued		9,602,890
Total number of warrants issued		364,439,176

Series D Convertible Preferre_2

Series D Convertible Preferred Stock (Details Narrative) - USD ($)	Jul. 28, 2020	Nov. 21, 2019	Nov. 15, 2019	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020	Sep. 11, 2020
Class of Stock [Line Items]
Preferred Stock, Par or Stated Value Per Share				$ 0.001		$ 0.001
FWHC HOLDINGS, LLC [Member]
Class of Stock [Line Items]
Warrant term							10 years
Warrants exercise price, per share							$ 0.014
Series D Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Dividends, Preferred Stock				$ 0	$ 278,476
Preferred Stock, Dividend Rate, Percentage					8.00%
Stock Issued During Period, Value, New Issues					$ 6,281,433
Debt Conversion, Converted Instrument, Shares Issued	15,773,363
Securities Purchase Agreement [Member] | FWHC HOLDINGS, LLC [Member]
Class of Stock [Line Items]
Stock issued during period new issue shares		146,998
Preferred Stock, Par or Stated Value Per Share		$ 0.001
Securities Purchase Agreement [Member] | Accredited Investors [Member] | Series D Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Share issued price per share			$ 40.817
Securities Purchase Agreement [Member] | Accredited Investors [Member] | Maximum [Member] | Series D Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Stock issued during period new issue shares			238,871
Securities Purchase Agreement [Member] | Accredite Investors [Member] | Series D Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Warrant term			10 years
Number of warrants to purchase common stock			14,669,757
Warrants exercise price, per share			$ 0.75

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Unrecognized tax positions	$ 0	$ 0

Subsequent Events (Details Narr

Subsequent Events (Details Narrative)	1 Months Ended
	Aug. 11, 2021shares
Subsequent Event [Member]
Subsequent Event [Line Items]
Conversion of stock, shares converted	3,633,900